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Background: Thoracoscopic talc poudrage induces peripheral blood granulocytosis and
lymphopenia. The aim of this study is to investigate the type of lymphopenia in patients
undergoing thoracoscopic talc poudrage.
Methods: We have measured peripheral blood lymphocyte subsets in 11 patients
undergoing thoracoscopic talc poudrage, before (baseline), at 24 and 48 h after the
procedure. Lymphocyte numbers were analysed by flow cytometry for the evaluation of
the CD3+, CD4+, CD8+ cells (total T-lymphocytes, helper T-lymphocytes, cytotoxic T-
lymphocytes, respectively), the CD19+ cells (B-lymphocytes), and the CD16+, CD56+ and
CD57+ cells (NK-cells). No anti-inflammatory medication was permitted before, during or
after the procedure.
Results: Absolute peripheral blood lymphocyte count significantly decreased following
thoracoscopic talc poudrage compared to baseline values (p ¼ 0:007). Similarly, peripheral
blood CD3+, CD4+ and CD8+ lymphocyte counts significantly decreased compared to
baseline (p ¼ 0:005, 0.02 and 0.03, respectively) with a more prominent reduction of CD3/
CD45RO memory cells. No significant difference was found in the absolute number of
CD19+, CD16+, CD56+, and CD57+ cells before and after thoracoscopic talc poudrage.Elsevier Ltd. All rights reserved.
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Talc poudrage decreases T-lymphocytes 1213Conclusion: Patients undergoing thoracoscopic talc poudrage display peripheral blood T-
lymphopenia following the procedure.
& 2006 Elsevier Ltd. All rights reserved.Introduction
The pleural space is a cavity of potential immunological
and/or inflammatory process, since the pleura is a highly
permeable layer closely related to local microcirculation.1
Although, it is generally accepted that any kind of
aggression, such as infectious, inflammatory or malignant
disease may affect the pleural space, little effort has been
made to understand the immunological and molecular
mechanisms underlying pleural disorders.2 The pleural
mesothelium responds to any aggression by actively recruit-
ing inflammatory phagocytic cells and allowing the move-
ment of proteins from the vascular compartment into the
pleural space.3 Acute inflammatory process is associated
with the development of an inflammatory cell rich pleural
effusion. A migration of neutrophils followed by mono-
nuclear phagocytes and lymphocytes is a characteristic
feature of this inflammation. These inflammatory cells move
from the vascular compartment into the pleural space.3
Talc is actually the agent of choice for chemical
pleurodesis, with an efficacy rate of more than 90%. It
may be administered as a powder by insufflations during
thoracoscopy,4–7 inducing fibrosis and inflammation in the
pleural cavity.8 Talc pleurodesis is generally well tolerated.
However, reports have stated minor side effects such as,
pleuritic pain during pleurodesis, nausea and fever after the
procedure.4,6 Fever after thoracoscopic talc poudrage
occurs in at least 20% of the patients who have been
included in prospective studies.9,10 We have recently
published a study showing that intra-pleural insufflation of
talc during thoracoscopy induces fever and systemic
inflammatory reaction.10 Inflammation was significant 24 h
after talc poudrage with a significant increase of C-reactive
proteine (CRP) in the serum, white blood cells and
neutrophil counts in the peripheral blood of the patients.
In parallel, we noted a significant decrease in patient
peripheral blood lymphocyte counts.10
However, discussion of the choice of sclerosing agent is
hampered by the lack of knowledge of the inflammatory
process. It is assumed that sclerosing agents may induce an
inflammatory response leading to a rapid adhesion of the
parietal and visceral pleura. In the literature, only scarce
information is available on the inflammatory mechanism
itself. Since we observed several humoral immune modifica-
tions in the peripheral blood related to talc poudrage, we
initiated a study to further investigate the alterations in the
number and function of lymphocytes.11 The aim of our study
is to assess peripheral blood lymphocyte subsets in order to
investigate the lymphopenia induced by thoracoscopic talc
poudrage. The clinical relevance of our report is to bring a
piece in the understanding of the systemic inflammatory
reaction due to talc pleurodesis.10 To our knowledge, there
is no published report studying specifically the talc-induced
peripheral blood lymphopenia in patients undergoing thor-
acoscopic talc poudrage.Methods
Data collection
From May 2004 to December 2004, blood samples from 11
consecutive patients undergoing thoracoscopic talc poud-
rage were analyzed after consent. Patient characteristics
are shown in Table 1. Blood samples are anyway drawn
before thoracoscopy (standard pre-procedure control) and
after the intervention to follow the patient’s clinical status.
Though, peripheral blood lymphocytes and their subpopula-
tions were evaluated before thoracoscopy (baseline) and
24 h (day 1) and 48 h (day 2) after thoracoscopy. We also
evaluated the same way blood eosinophils. Following the
procedure, patients had a baseline treatment for the pain
with fentanyl citrate patch 25mg every 72 h. In case of
persistent pain, patients received supplement of parenteral
narcotics (morphine) on request. No anti-inflammatory or
antipyretic medications were permitted before, during, or
after the procedure.Thoracoscopy
Thoracoscopy has been approved by the Internal Review
Board (IRB) of the Heraklion University Hospital, as a
standard procedure in the diagnosis and therapy (talc
pleurodesis) of pleural effusions. Though, no further IRB
was necessary to perform this procedure, as it is done for
routine clinical practice (diagnosis and therapy of pleural
effusions). Patients were admitted the same morning of
thoracoscopy and were discharged on the day of chest tube
removal. During the procedure, blood pressure, oxygen
saturation, and electrocardiogram, were monitored. Oxygen
supplementation was provided if needed. In case of pain
during thoracoscopy, patients received supplement of
parenteral narcotics (morphine) on request. No general
anesthesia was used at any case.
Thoracoscopy was performed in the lateral decubitus
position using single port of entry, under local anesthesia
with 1% lignocaine. Patients were administered morphine
0.5mg as needed. A 7mm trocar was inserted into the fifth
or sixth intercostal space along the mid-axillary line. After
evacuation of the pleural fluid, a 01 optical telescope was
inserted and connected to a light source. The entire pleural
cavity was then inspected, at times requiring supplemental
air insufflation.
Sterile asbestos-free talc (Steritalc*, Novatech, La Ciotat
France) was insufflated into the pleural space of patients for
pleurodesis (4 g of talc for malignant pleural effusion and 2 g
for pneumothorax). At the end of the procedure, a chest
tube (24–28 French gauge) was inserted and connected to
underwater seal with a negative suction of 20 cm H2O for at
least 2 days. Chest tube was removed when less than 100ml
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Table 1 Patients’ characteristics.
Thoracoscopic talc
poudrage (n ¼ 11)
Age
(mean7SD) (range) 65.5715.8 (43–93)
Sex
Male (n-%) 7 (63.6%)
Female (n-%) 4 (36.4%)
Diagnosis
Malignant (n-%) 10 (90.9%)
Benign (n-%) 1 (9.1%)
Days of pleural drainage
(mean7SD) (range) 3.571.4 (2–7)
Side of thoracoscopy
Left 8 (72.7%)
Right 3 (27.3%)
Pleural fluid pH
(mean7SD) (range) 7.4070.07 (7.30–7.49)
Pleural fluid LDH (IU/L)
(mean7SD) (range) 2817137 (130–624)
Pleural protein (gr/dL)
(mean7SD) (range) 4.370.6 (3.2–5.1)
M.E. Froudarakis et al.1214of pleural fluid was drained over a 24 h period in patients
who underwent pleurodesis.
Enumeration of blood cells
Venous blood samples were drawn directly into sterile tubes
containing EDTA-K3 (0.17mol/l) as anticoagulant. Blood cell
enumeration and white blood cell differential counts
(lymphocytes and eosinophils) were performed in a Coulter
STKS hemocytometer (Coulter Electronics, UK). Values were
expressed in absolute numbers of cells per microliter (ml) of
blood. All samples were studied within 1–2 h following blood
collection without storage. The same blood samples were
subsequently used for analysis of lymphocyte subsets.
Percentages of lymphocyte subsets were determined on
the basis of cell surface marker analysis, carried out by
direct immunofluorescence using a panel of fluorochrome-
conjugated monoclonal antibodies (MoAbs). The absolute
cell number of each cell subset (cells/ml) was calculated
from the respective proportion of positive cells and the
number of lymphocytes per microliter of blood.
Immunostaining of blood samples
In all assays, the ‘‘label-lyse-fix’’ method was applied. In
brief, 100 ml blood sample were mixed into small tubes with
the appropriate amount of fluoroisothiocyanate (FITC)- and/
or phycoerythrin (PE)-labeled MoAb. All MoAbs were used in
saturating concentrations. An FITC- or PE-conjugated mouse
isotypic IgG served as negative control for each MoAb.
Mixtures were incubated for 20min at room temperature;
this was followed by red blood cell lysis with the addition of
0.12% formic acid solution (Q-Prep reagent system, Coulter).
The remaining white blood cells were fixed with 1%
paraformaldehyde, washed in phosphate-buffered saline(PBS, pH 7.4), resuspended in paraformaldehyde solution,
and studied immediately. The following mouse anti-human
MoAbs were used: FITC-or PE-conjugated anti-CD3 (UCHT1),
anti- CD4 (13B8.2), anti-CD8 (B9.11), anti-CD19 (J4.119),
anti-CD16 (3G8), anti-CD57 (NCI), anti-CD56 (N901), anti-
CD45RA (J.33), and anti-CD45RO (UCHL1). Two-color flow
cytometry was used for the detection of CD56/CD57,
CD3/CD45RA, CD3/CD45RO double positive cells, represent-
ing the NK-cells, the naı¨ve and memory T-lymphocytes,
respectively. All antibodies were purchased from Beckman
Coulter.
Flow-cytometric analysis
Cells were evaluated for membrane fluorescence using an
Epics ELITE model of flow cytometer (CoulterElectronics,
UK) in the gate of cell with low forward and low side-scatter
properties where more than 98% lymphocytes are included
(Fig. 1). In each case, 5 103 positive-gated events were
counted.
Statistical analysis
We used a statistical software package (StatView
TM
, version
4.5; Abacus Concepts Inc., Berkeley CA, USA) for the
statistical evaluation of our data. The mean values and
standard deviation (SD) were calculated for continuous
data. Continuous data were compared using the Student t-
test. Analysis of variance (ANOVA) was used to evaluate
differences in repeated measurements. A value of po0.05
was considered to be statistically significant.
Results
Peripheral blood lymphocytes
Peripheral blood lymphocyte counts at baseline were
(mean7SD/ml blood) 19637375 (range: 1349–2548). Lym-
phocytes decreased on Day 1 at 14677332 (range:
1010–1970) and on Day 2 at 16127428 (range: 858–2213).
The overall decrease of lymphocyte counts was statistically
significant (p ¼ 0:007) (Fig. 2). Lymphocyte reduction was
more pronounced on Day 1 (p ¼ 0:009) than on Day 2
(p ¼ 0:01) compared to baseline values.
Peripheral blood eosinophil counts at baseline were
(mean7SD/ml blood) 4497374 (range: 81–1272). Eosino-
phils decreased on Day 1 at 1167143 (range: 0–414) and on
Day 2 at 4827218 (range: 191–768). The overall decrease of
eosinophil numbers was statistically significant (p ¼ 0:005)
(Fig. 3). Eosinophil reduction was seen only on Day 1 in
comparison to baseline values (p ¼ 0:005).
T-cell lymphocyte subsets
T-cell subpopulations defined by the CD3, CD4, and CD8 cell
surface markers, were all significantly decreased in our
patients at day 1 and 2 compared to baseline (p ¼ 0:005,
0.022, 0.03, respectively) (Table 2 and Figs. 4–6). The CD4+/
CD8+ cell ratio did not change significantly (p ¼ 0:24),
suggesting a parallel diminution of both CD4+ and CD8+
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Figure 2 Evolution of lymphocytes (mean/ml blood) before
(baseline), 24 h (day 1) and 48 h (day 2) after thoracoscopic talc
poudrage.
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Figure 3 Evolution of eosinophils (mean/ml blood) before (day
0), 24 h (day 1) and 48 h (day 2) after thoracoscopic talc
poudrage (overall p ¼ 0:005).
Figure 1 Flow-cytometric analysis of lymphocyte subsets. The left scattergram shows forward scatter (FSC) versus side scatter
(SSC) to allow gating on lymphocytes (low FSC and low SSC) (R1). The right scattergram shows CD45RO fluorescence (FITC) gated on
R1 to show the decrease in CD45RO expression in day 1 (D-1) and day 2 (D-2) compared to baseline (D-0). The background
fluorescence obtained from the isotypic control is also shown.
Table 2 Peripheral blood T-cell subsets of the patients
studied.
Cells (n ¼ 11) Baseline Day 1 Day 2 Overall p
CD3+ 14627332 10467290* 11717384* 0.005
CD4+ 8857189 5887236 6557255** 0.022
CD8+ 5797342 4287182 4057254* 0.03
CD4+/CD8+ 1.7570.89 1.4570.37 2.0270.95 0.24
*po0.05 from baseline.
**po0.01 from baseline.
Values are expressed as mean/ml7SD.
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Figure 4 Evolution of CD3+ (mean/ml blood) before (baseline),
24 h (day 1) and 48 h (day 2) after thoracoscopic talc poudrage.
Talc poudrage decreases T-lymphocytes 1215T-cell subpopulations (Table 2). To probe further the
mechanisms underlying T-cell lymphopenia in the patients,
we evaluated the CD3/CD45RA and CD3/CD45RO cell subsets
representing the naı¨ve and memory cells, respectively(Table 3). Although the overall decrease of both naı¨ve and
memory cells was not significant, we observed a significant
decrease from baseline on days 1 and 2 for the memory
cells, and on day 1 for the naı¨ve cells (Table 3, Fig. 1).The CD57 cell phenotype
The CD57 cell phenotype of peripheral blood lymphocytes is
illustrated in Table 4. No significant differences were found
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Table 3 Peripheral blood memory (CD3+/CD45R0+) and
naı¨ve (CD3+/CD45RA+) cells of the patients studied.
Cells (n ¼ 11) Baseline Day 1 Day 2 Overall p
CD3+/CD45RO+ 4917200 3757155* 3777192* 0.08
CD3+/CD45RA+ 3837134 2827136* 3107164 0.15
*po0.05 from baseline.
Values are expressed as mean/ml7SD.
Table 4 Peripheral blood B-cells and NK-cell pheno-
types of the patients studied.
Cells (n ¼ 11) Baseline Day 1 Day 2 Overall p
CD16+ 3677288 2657115 2237135 0.06
CD19+ 1457133 113786 1197117 0.28
CD56+ 2447142 2577166 2077175 0.45
CD57+ 4687212 4047248 4597277 0.39
CD56+/CD57+ 129780 1577139 1447145 0.45
Values are expressed as mean/ml7SD.
Overall p=0.022
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Figure 5 Evolution of CD4+ (mean/ml blood) before (baseline),
24 h (day 1) and 48 h (day 2) after thoracoscopic talc poudrage.
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Figure 6 Evolution of CD8+ (mean/ml blood) before (baseline),
24 h (day 1) and 48 h (day 2) after thoracoscopic talc poudrage.
M.E. Froudarakis et al.1216in the mean number of CD57+ cells or the CD56+/CD57+ cells
between day 1, 2 and baseline. Since many CD57+ cells are
in fact T lymphocytes, it is probable that their diminution in
our patients is a consequence of the aforementioned
decrease of the CD3+ T-cell populations. No significant
correlation was demonstrated between the numbers of
circulating neutrophils and the numbers of CD57+ cells in the
subjects studied.B-cell and NK-cell populations
Patient B-cell and NK-cell populations are presented in Table
4. The numbers of peripheral blood B-cells, defined by the
expression of CD19 cell surface antigen, did not differstatistically between baseline, day 1 or 2. Also, the mean
numbers of NK cells defined by the expression of CD16 and/
or CD56 cell surface markers were not significantly different
between baseline, day 1 or 2. Both CD16+ and CD56+ cell
counts were not correlated with the numbers of circulating
neutrophils.Discussion
We have previously shown that patients undergoing talc
poudrage display peripheral blood lymphopenia following
the procedure.10 In the current report we investigated
whether this lymphopenia concerns T- and/or B- and NK
lymphocyte subsets. To the best of our knowledge this is the
first report investigating the effect of thoracoscopic talc
pleurodesis in lymphocyte subsets.
The helper to suppressor T-cell ratio in the peripheral
blood of our patients at baseline (Table 2) was similar to that
previously reported for healthy subjects.12 Other authors
have already reported similar results in patients with
malignancies including breast cancer13 and melanoma.14,15
A possible explanation is that patients with localized
carcinoma display total T-cell subpopulations similar to
those of healthy subjects. Indeed, our 10 patients with
carcinomatous pleurisy had limited disease and were all in
good shape (performance score of Eastern Cooperative
Oncology Group (ECOG): 0 or 1), with life expectancy for
at least 6 months, to undergo thoracoscopic talc pleurod-
esis. In contrast, patients with extensive metastatic disease
and low performance status have been reported to display
CD4+/CD8+ ratio o1 as in immunocompromized sub-
jects.13,15
Our patients had decreased T-lymphocyte numbers in
peripheral blood 24 h after thoracoscopic talc poudrage
(Table 2). The lymphocytes probably decreased due to
enhanced extravasation in the pleura.3 In favor of this
hypothesis is the prominent decrease of the memory CD3/
CD45RO lymphocyte subsets in the patients. An accumula-
tion of lymphocytes, especially memory T-lymphocytes, in
pleural fluid has been reported to occur in intrapleural
inflammatory processes such as neoplastic and tuberculous
effusions.3,16 This transient T-lymphocyte extravasation may
result in transient lymphopenia. This phenomenon is
probably followed by spontaneous expansion of the remain-
ing T-cells in the periphery to restore the original T-cell pool
size and maintain homeostasis.17 Consistent with this
hypothesis was the partial recovery of the T-lymphocytes
in patients’ peripheral blood 48 h after the talc poudrage.
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Talc poudrage decreases T-lymphocytes 1217In our patients, the acute development of fever and
neutrophilia, which subsided after 24 h advocates for a
systemic acute inflammatory response.10,18 Such reactions
are normally accompanied by endogenous steroid produc-
tion as a compensatory mechanism. Elevated levels of
circulating glucocorticoids result in temporary lymphopenia
due to redistribution of peripheral blood lymphocytes to
other lymphoid compartments and depletion of recirculating
lymphocytes. Usually, the lymphopenia resolves after 24 h,
whereas T-cells are selectively depleted with a predilection
for the memory T-cell subset.19
Eosinophils are also profoundly decreased 4–6 h after
corticosteroid administration through an identical mechan-
ism involving migration of eosinophils to other tissues.19
Consistent with all of the above, our study population
displayed a parallel fluctuation of both lymphocyte and
eosinophil count, while NK cells were the only lymphocyte
subsets that remained unaffected (Table 4), as expected in
innate immune system activation. Additionally, the slight
but not significant decrease of B-cells along with the
persistent reduction of T-memory cells after 48 h further
concurs for the aforementioned mechanism (Tables 3 and 4).
Interleukin-8 (IL-8) is a cytokine with pleiotropic effects
which is secreted during acute systemic inflammation, when
it stimulates the synthesis of acute-phase proteins.20 In
addition, IL-8 is a member of the CXC chemokine family and
can evoke T-lymphocyte migration into the pleural space.21
Although pleural fluid lymphocyte subsets were not assessed
in the current study, it is tempting to speculate that
production of IL-8 from stimulated mesothelial cells3 after
thoracoscopic talc poudrage induced the recruitment of
peripheral blood T-cells in the pleural space, resulting in the
observed T-cell decrease in the periphery. Data on the
phenotype of pleural lymphocytes have been reported in
pleural immune reactions in case of malignant and tubercu-
lous pleural effusion.2,22,23 However, data are lacking
concerning the type and role of these cells in the process
of pleurodesis by a sclerosant agent.2
We concluded that patients undergoing thoracoscopic talc
poudrage display peripheral blood T-lymphopenia following
the procedure, probably due to enhanced extravasation in
the pleura.
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